Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study to Evaluate Cinacalcet in Children With Chronic Kidney Disease
Phase 1
Completed
- Conditions
- Chronic Kidney DiseaseHyperparathyroidism, SecondarySecondary Hyperparathyroidism
- Interventions
- First Posted Date
- 2011-02-04
- Last Posted Date
- 2020-06-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 14
- Registration Number
- NCT01290029
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
Study of Apremilast to Evaluate the Safety and Effectiveness for Patients With Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 237
- Registration Number
- NCT01285310
- Locations
- 🇺🇸
TriWest Research Associates, La Mesa, California, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
🇺🇸Stanford University Medical Center, Palo Alto, California, United States
AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)
Phase 3
Terminated
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
- Interventions
- Drug: Placebo plus PLDDrug: AMG386 plus PLD
- First Posted Date
- 2011-01-21
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 223
- Registration Number
- NCT01281254
- Locations
- 🇬🇧
Research Site, Poole, United Kingdom
Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) Patients
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- Drug: TIS (Tobramycin Inhalation Solution)Drug: MP-376 (Levofloxacin Solution for Inhalation)
- First Posted Date
- 2011-01-05
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 282
- Registration Number
- NCT01270347
- Locations
- 🇺🇸
Childrens Hospital, Los Angeles, California, United States
🇺🇸Albany Medical College #2, Albany, New York, United States
🇫🇷Hôpital Pellegrin Enfants - CHU Bordeaux, Bordeaux, France
To Evaluate the Safety of Long-term Use of HPN-100 in the Management of Urea Cycle Disorders (UCDs)
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 88
- Registration Number
- NCT01257737
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Seattle Children's Hospital, Seattle, Washington, United States
Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer
Phase 1
Completed
- Conditions
- CarcinomaFallopian Tube CancerOvarian CancerPrimary Peritoneal Cancer
- Interventions
- Drug: AMG 386, paclitaxel and carboplatin
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 27
- Registration Number
- NCT01253681
- Locations
- 🇪🇸
Research Site, Madrid, Spain
A Study of AMG 337 in Subjects With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- TumorsOncology PatientsAdvanced MalignancyCancerOncologyAdvanced Solid Tumors
- Interventions
- First Posted Date
- 2010-12-03
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT01253707
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2010-11-17
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 159
- Registration Number
- NCT01242917
Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque Psoriasis
Phase 3
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: 2=Clobetasol propionate foamDrug: 1=Etanercept
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2018-08-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 592
- Registration Number
- NCT01235442
A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid Tumors
Phase 1
Completed
- Conditions
- Histologically or Cytologically Documented Solid Tumors
- Interventions
- First Posted Date
- 2010-11-05
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 57
- Registration Number
- NCT01235416
© Copyright 2025. All Rights Reserved by MedPath